Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Similar articles for PubMed (Select 24635140)

1.

Review of bortezomib treatment of antibody-mediated rejection in renal transplantation.

Ejaz NS, Alloway RR, Halleck F, Dürr M, Budde K, Woodle ES.

Antioxid Redox Signal. 2014 Dec 10;21(17):2401-18. doi: 10.1089/ars.2014.5892. Epub 2014 Apr 28. Review.

PMID:
24635140
2.

Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.

Walsh RC, Everly JJ, Brailey P, Rike AH, Arend LJ, Mogilishetty G, Govil A, Roy-Chaudhury P, Alloway RR, Woodle ES.

Transplantation. 2010 Feb 15;89(3):277-84. doi: 10.1097/TP.0b013e3181c6ff8d.

PMID:
20145517
3.

Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial.

Eskandary F, Bond G, Schwaiger E, Kikic Z, Winzer C, Wahrmann M, Marinova L, Haslacher H, Regele H, Oberbauer R, Böhmig GA.

Trials. 2014 Apr 3;15:107. doi: 10.1186/1745-6215-15-107.

4.

Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.

Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, Roy-Chaudhury P, Govil A, Mogilishetty G, Rike AH, Cardi M, Wadih G, Tevar A, Woodle ES.

Transplantation. 2008 Dec 27;86(12):1754-61. doi: 10.1097/TP.0b013e318190af83.

PMID:
19104417
5.

Antibody-mediated rejection in kidney transplantation: an update.

Lucas JG, Co JP, Nwaogwugwu UT, Dosani I, Sureshkumar KK.

Expert Opin Pharmacother. 2011 Mar;12(4):579-92. doi: 10.1517/14656566.2011.525219. Epub 2011 Feb 5. Review.

PMID:
21294653
6.

Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation.

Sureshkumar KK, Hussain SM, Marcus RJ, Ko TY, Khan AS, Tom K, Vivas CA, Parris G, Jasnosz KM, Thai NL.

Clin Nephrol. 2012 Mar;77(3):246-53. Review.

PMID:
22377258
7.

Proteasome inhibitor treatment of antibody-mediated allograft rejection.

Woodle ES, Alloway RR, Girnita A.

Curr Opin Organ Transplant. 2011 Aug;16(4):434-8. doi: 10.1097/MOT.0b013e328348c0e5.

PMID:
21753709
8.

Clinical and investigational use of proteasome inhibitors for transplant rejection.

Sadaka B, Alloway RR, Woodle ES.

Expert Opin Investig Drugs. 2011 Nov;20(11):1535-42. doi: 10.1517/13543784.2011.618494. Epub 2011 Sep 15. Review.

PMID:
21916809
9.

Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients.

Morrow WR, Frazier EA, Mahle WT, Harville TO, Pye SE, Knecht KR, Howard EL, Smith RN, Saylors RL, Garcia X, Jaquiss RD, Woodle ES.

Transplantation. 2012 Feb 15;93(3):319-24. doi: 10.1097/TP.0b013e31823f7eea.

10.

Proteasome inhibition for antibody-mediated allograft rejection.

Sadaka B, Alloway RR, Shields AR, Schmidt NM, Woodle ES.

Semin Hematol. 2012 Jul;49(3):263-9. doi: 10.1053/j.seminhematol.2012.04.008. Review.

PMID:
22726550
11.
12.

Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction.

Stuckey LJ, Kamoun M, Chan KM.

Ann Pharmacother. 2012 Jan;46(1):e2. doi: 10.1345/aph.1Q509. Epub 2011 Dec 27.

PMID:
22202499
13.

Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies.

Gupta G, Abu Jawdeh BG, Racusen LC, Bhasin B, Arend LJ, Trollinger B, Kraus E, Rabb H, Zachary AA, Montgomery RA, Alachkar N.

Transplantation. 2014 Jun 27;97(12):1240-6. doi: 10.1097/01.TP.0000442503.85766.91.

PMID:
24937198
14.

Proteasome inhibitor therapy for antibody-mediated rejection.

Woodle ES, Walsh RC, Alloway RR, Girnita A, Brailey P.

Pediatr Transplant. 2011 Sep;15(6):548-56. doi: 10.1111/j.1399-3046.2011.01543.x. Review.

PMID:
21884344
15.

Proteasome inhibition reduces donor-specific antibody levels.

Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, Roy-Chaudhury P, Govil A, Mogilishetty G, Rike AH, Cardi M, Wadih G, Brown E, Tevar A, Woodle ES.

Transplant Proc. 2009 Jan-Feb;41(1):105-7. doi: 10.1016/j.transproceed.2008.10.073.

PMID:
19249489
16.

Management of antibody-mediated rejection in transplantation.

Sadaka B, Alloway RR, Woodle ES.

Surg Clin North Am. 2013 Dec;93(6):1451-66. doi: 10.1016/j.suc.2013.08.002. Epub 2013 Sep 29. Review.

PMID:
24206861
17.

Efficacy of bortezomib for reducing donor-specific antibodies in children and adolescents on a steroid minimization regimen.

Nguyen S, Gallay B, Butani L.

Pediatr Transplant. 2014 Aug;18(5):463-8. doi: 10.1111/petr.12274. Epub 2014 May 12.

PMID:
24814755
18.

Bortezomib use in a pediatric cardiac transplant center.

Zinn MD, L'Ecuyer TJ, Fagoaga OR, Aggarwal S.

Pediatr Transplant. 2014 Aug;18(5):469-76. doi: 10.1111/petr.12300. Epub 2014 Jun 14.

PMID:
24931171
19.

Proteasome inhibitor-based therapy for antibody-mediated rejection.

Walsh RC, Alloway RR, Girnita AL, Woodle ES.

Kidney Int. 2012 Jun;81(11):1067-74. doi: 10.1038/ki.2011.502. Epub 2012 Feb 15. Review.

PMID:
22336990
20.

Protective immunity and use of bortezomib for antibody-mediated rejection in a pediatric kidney transplant recipient.

Claes DJ, Yin H, Goebel J.

Pediatr Transplant. 2014 Jun;18(4):E100-5. doi: 10.1111/petr.12256. Epub 2014 Apr 12.

PMID:
24725066
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk